Posted by Michael Wonder on 12 Sep 2024
Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus
12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for the treatment of adolescents 10-17 years of age with type 2 diabetes mellitus because Boehringer Ingelheim did not provide an evidence submission.
NICE will review this decision if Boehringer Ingelheim decides to make a submission.
